☰

Sheenu Chandwani, Ph.D. - Publications

Affiliations: 
2012 Epidemiology Rutgers University, New Brunswick, New Brunswick, NJ, United States 
Area:
Public Health, Epidemiology, Oncology, African American Studies
Tree Info Similar researchers PubMed Report error

25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Velcheti V, Chandwani S, Chen X, Piperdi B, Burke T. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival. Clinical Lung Cancer. PMID 32376116 DOI: 10.1016/J.Cllc.2020.02.023  0.332
2019 Velcheti V, Chandwani S, Chen X, Pietanza MC, Piperdi B, Burke T. Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices. Immunotherapy. PMID 31774363 DOI: 10.2217/Imt-2019-0177  0.334
2019 Meng W, Ou W, Chandwani S, Chen X, Black W, Cai Z. Temporal phenotyping by mining healthcare data to derive lines of therapy for cancer. Journal of Biomedical Informatics. 103335. PMID 31689549 DOI: 10.1016/J.Jbi.2019.103335  0.335
2019 Velcheti V, Chandwani S, Chen X, Pietanza MC, Burke T. First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment. Immunotherapy. PMID 31181973 DOI: 10.2217/Imt-2019-0061  0.34
2019 El Ferjani B, Chandwani S, Hirschmann M, Dibaj S, Roarty E, Zhang J, Rinsurnogkawong W, Lewis J, Lee J, Roth JA, Swisher S, Heymach JV, Burke T, Simon GR. HSR19-085: A Real World Observational Assessment of the Impact of Immunotherapy on the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Journal of the National Comprehensive Cancer Network. 17: HSR19-085. DOI: 10.6004/Jnccn.2018.7202  0.348
2019 Velcheti V, Chandwani S, Chen X, Pietanza MC, Burke T. Abstract 3307: Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC) Cancer Research. 79: 3307-3307. DOI: 10.1158/1538-7445.Am2019-3307  0.35
2019 Altini M, Massa I, Balzi W, Gentili N, Foca F, Danesi V, Manunta S, Burgio M, Cravero P, Ejzykowicz F, Chandwani S, Delmonte A. Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy Annals of Oncology. 30: ii63-ii64. DOI: 10.1093/Annonc/Mdz063.074  0.364
2019 Williams L, Shi Q, El Ferjani B, Hirschmann M, Ponce D, Dibaj S, Chandwani S, Roarty E, Rinsurongkawong W, Lewis J, Burke T, Cleeland C, Lee J, Roth J, Swisher S, et al. MA19.03 Differences in Symptom Burden Between Responsive and Progressive Disease in Advanced Non-Small Cell Lung Cancer (aNSCLC) Journal of Thoracic Oncology. 14: S327. DOI: 10.1016/J.Jtho.2019.08.657  0.33
2019 Altini M, Massa I, Balzi W, Gentili N, Foca F, Danesi V, Manunta S, Ejzykowicz F, Chandwani S, Burgio M, Cravero P, Verlicchi A, Bronte G, Crino L, Delmonte A. EP1.16-04 Real World Clinical Outcomes for Metastatic Non-Small Cell Lung Cancer (mNSCLC) at IRST Italy Journal of Thoracic Oncology. 14: S1065-S1066. DOI: 10.1016/J.Jtho.2019.08.2369  0.355
2019 Shi Q, Williams L, El Ferjani B, Hirschmann M, Ponce D, Dibaj S, Chandwani S, Roarty E, Rinsurongkawong W, Lewis J, Burke T, Cleeland C, Lee J, Roth J, Swisher S, et al. P1.16-31 Body Mass Index Relating to Patient-Reported Symptoms in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 14: S599. DOI: 10.1016/J.Jtho.2019.08.1257  0.342
2019 Velcheti V, Chandwani S, Chen X, Piperdi B, Burke T. P1.16-15 Rates of Systemic Anticancer Therapy (SACT) for Advanced Non-Small Cell Lung Cancer (aNSCLC) in the US, 2011–2018 Journal of Thoracic Oncology. 14: S592. DOI: 10.1016/J.Jtho.2019.08.1241  0.345
2018 Huang M, Pietanza MC, Samkari A, Pellissier J, Burke T, Chandwani S, Kong F, Pickard AS. Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer. Pharmacoeconomics. PMID 30515719 DOI: 10.1007/S40273-018-0752-0  0.358
2018 Velcheti V, Chandwani S, Chen X, Pietanza M, Burke T. First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices Annals of Oncology. 29: x18. DOI: 10.1093/Annonc/Mdy486.002  0.354
2018 Williams L, Dibaj S, Chandwani S, Vaghani V, Shi Q, Hirschmann M, Landry L, Roarty E, Zhang J, Rinsurnogkawong W, Lewis J, Burke T, Cleeland C, Lee J, Roth J, et al. P3.01-109 Real-World Patient-Reported Outcome Assessment of Patients with Metastatic Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 13: S907-S908. DOI: 10.1016/J.Jtho.2018.08.1670  0.353
2018 Vaghani V, Chandwani S, Hirschmann M, Dibaj S, Landry L, Roarty E, Zhang J, Rinsurnogkawong W, Lewis J, Lee J, Roth JJA, Swisher S, Heymach J, Burke T, Simon G. P3.01-91 Computing the Impact of Immunotherapy on the Non-Small Cell Lung Cancer (NSCLC) Therapeutic Landscape Journal of Thoracic Oncology. 13: S901-S902. DOI: 10.1016/J.Jtho.2018.08.1651  0.338
2017 Chandwani S, Vaghani V, Hirschmann M, Lacerda Landry L, Roarty E, Zhang J, Shi Q, Rinsurnogkawong W, Lewis J, Williams L, Cleeland C, Burke T, Lee J, Roth J, Swisher S, et al. P2.04-014 Computing the Impact of Immunotherapy on NSCLC Landscape: The Advanced Non-Small Cell Lung Cancer Holistic Registry (ANCHoR) Journal of Thoracic Oncology. 12: S2403. DOI: 10.1016/J.Jtho.2017.11.027  0.342
2015 Llanos AA, Chandwani S, Bandera EV, Hirshfield KM, Lin Y, Ambrosone CB, Demissie K. Associations between sociodemographic and clinicopathological factors and breast cancer subtypes in a population-based study. Cancer Causes & Control : Ccc. 26: 1737-50. PMID 26376894 DOI: 10.1007/S10552-015-0667-4  0.621
2015 George P, Chandwani S, Gabel M, Ambrosone CB, Rhoads G, Bandera EV, Demissie K. Diagnosis and surgical delays in African American and white women with early-stage breast cancer. Journal of Women's Health (2002). 24: 209-17. PMID 25650628 DOI: 10.1089/Jwh.2014.4773  0.697
2015 Goyal S, Chandwani S, Haffty BG, Demissie K. Effect of travel distance and time to radiotherapy on likelihood of receiving mastectomy. Annals of Surgical Oncology. 22: 1095-101. PMID 25245129 DOI: 10.1245/S10434-014-4093-8  0.618
2015 Kurtyka K, Gaur S, Mehrotra N, Chandwani S, Janevic T, Demissie K. Adverse Outcomes Among Asian Indian Singleton Births in New Jersey, 2008-2011. Journal of Immigrant and Minority Health / Center For Minority Public Health. 17: 1138-45. PMID 25047404 DOI: 10.1007/S10903-014-0075-Y  0.495
2015 Llanos AAM, Chandwani S, Hirshfield KM, Lin Y, Bandera EV, Ambrosone CB, Demissie K. Abstract B47: Associations between clinicopathological features and breast cancer subtypes Cancer Epidemiology, Biomarkers & Prevention. 24. DOI: 10.1158/1538-7755.Disp14-B47  0.59
2015 George P, Chandwani S, Gabel M, Ambrosone CB, Rhoads G, Bandera EV, Demissie K. Diagnosis and Surgical Delays in African American and White Women with Early-Stage Breast Cancer Journal of Women's Health. 24: 209-217. DOI: 10.1089/jwh.2014.4773  0.687
2014 Chandwani S, George PA, Azu M, Bandera EV, Ambrosone CB, Rhoads GG, Demissie K. Role of preoperative magnetic resonance imaging in the surgical management of early-stage breast cancer. Annals of Surgical Oncology. 21: 3473-80. PMID 24912611 DOI: 10.1245/S10434-014-3748-9  0.673
2014 Chandwani S, Stevinson KL, Mehnert JM. Predictors of receipt of immunotherapy for stage II and III melanoma in United States clinical practice. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E20003  0.354
2013 Weng FL, Chandwani S, Kurtyka KM, Zacker C, Chisholm-Burns MA, Demissie K. Prevalence and correlates of medication non-adherence among kidney transplant recipients more than 6 months post-transplant: a cross-sectional study. Bmc Nephrology. 14: 261. PMID 24289809 DOI: 10.1186/1471-2369-14-261  0.476
Show low-probability matches.